论文部分内容阅读
目的观察山奈酚对糖尿病大鼠骨髓来源内皮祖细胞管腔形成能力的影响,为2型糖尿病的治疗提供参考依据。方法体外原代培养内皮祖细胞,采用牛血清白蛋白糖基化终末产物(BSA-AGEs)(100mg/L)与山奈酚(2μM,10μM,50μM)分别作用于内皮祖细胞24h,M~atrigel胶上观察其管腔形成能力。结果山奈酚(2μM,10μM,50μM)三组的EPCs管腔形成数目分别是4.7/×100视野,5.2/×100视野和6.1/×100视野,与AGEs组(4.3/×100视野)比较,组间比较差异有统计学意义(F=55.58,P<0.05)。结论山奈酚能够改善糖尿病内皮功能障碍,提高微血管管腔形成的能力,对2型糖尿病性心肌病的治疗和糖尿病血管并发症的预防有效。
Objective To observe the effect of kaempferol on the ability of bone marrow-derived endothelial progenitor cells to form in the lumen of diabetic rats and to provide a reference for the treatment of type 2 diabetes mellitus. Methods EPCs were primarily cultured in vitro. Endothelial progenitor cells were treated with BSA-AGEs (100 mg / L) and kaempferol (2 μM, 10 μM, 50 μM) atrigel gel observation of its lumen formation ability. Results The number of EPCs in three groups of kaempferol (2μM, 10μM and 50μM) was 4.7 / × 100, 5.2 / × 100 and 6.1 / × 100, respectively. Compared with AGEs group (4.3 / × 100 field) The difference between the two groups was statistically significant (F = 55.58, P <0.05). Conclusion Kaempferol can improve diabetic endothelial dysfunction and improve the ability of microvascular lumen formation, and it is effective in the treatment of type 2 diabetic cardiomyopathy and prevention of diabetic vascular complications.